Results 31 to 40 of about 7,787 (204)

Access to diagnosis and treatment of Chagas disease/infection in endemic and non-endemic countries in the XXI century. [PDF]

, 2007
In this article, Médicos Sin Fronteras (MSF) Spain faces the challenge of selecting, piecing together, and conveying in the clearest possible way, the main lessons learnt over the course of the last seven years in the world of medical care for Chagas ...
Albajar-Vinas, P, Bernal, O, Bulla, D, Morote, S, Villa, L   +4 more
core   +4 more sources

In Vitro Benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma cruzi Strains Belonging to Discrete Typing Units TcI, TcII, and TcV

Pathogens, 2019
We ascertain the in vitro Benznidazole (BZN) and Nifurtimox (NFX) susceptibility pattern of epimastigotes, trypomastigotes, and amastigotes of 21 T. cruzi strains, from patients, reservoir, and triatomine bugs of various geographic origins.
Susana Revollo, Bruno Oury, Andrea Vela, Michel Tibayrenc, Denis Sereno   +4 more
doaj   +1 more source

Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma cruzi-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes

Frontiers in Immunology, 2018
Background: In contrast to adults, Trypanosoma cruzi-infected children have more broadly functional Trypanosoma cruzi-specific T cells, and the total T-cell compartment exhibits fewer signs of immune exhaustion.
María C. Albareda, María A. Natale, Ana M. De Rissio, Marisa Fernandez, Alicia Serjan, María G. Alvarez, Gretchen Cooley, Huifeng Shen, Rodolfo Viotti, Jacqueline Bua, Melisa D. Castro Eiro, Myriam Nuñez, Laura E. Fichera, Bruno Lococo, Karenina Scollo, Rick L. Tarleton, Susana A. Laucella, Susana A. Laucella   +17 more
doaj   +1 more source

ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.

PLoS Neglected Tropical Diseases, 2023
BackgroundMeasurement of the success of antitrypanosomal treatment for Chagas disease is difficult, particularly in the chronic phase of the disease, because anti-Trypanosoma cruzi antibodies persist in serum for prolonged periods. We studied the effects
Rocio Rivero, Mónica Inés Esteva, Erya Huang, Leylen Colmegna, Jaime Altcheh, Ulrike Grossmann, Andrés Mariano Ruiz, CHICO and CHICO SECURE Study Groups   +7 more
doaj   +1 more source

Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis [PDF]

, 2018
Interest in nitroheterocyclic drugs for the treatment of infectious diseases has undergone a resurgence in recent years. Here we review the current status of monocyclic and bicyclic nitroheterocyclic compounds as existing or potential new treatments for ...
Alan H. Fairlamb, Alliance T.B., Altcheh J., Andrade H.M., Andrade S.G., Andrade S.G., Andrews K.T., Ang C.W., Araldi R.P., Aubé J., Bahia M.T., Bahia M.T., Balasubramanian B., Barreto-Bergter E., Berriman M., Bisser S., Blumenstiel K., Boiani M., Brener Z., Bruhn D.F., Bustamante J.M., Campos M.C., Campos M.C., Chung M.C., Collins A.R., Darsaud A., de Andrade A.L., Deavall D.G., Dikhit M.R., Docampo R., Docampo R., Docampo R., Dodd M.C., Dogra M., El-Sayed N.M., Enanga B., Eperon G., Fabbro D.L., Fairlamb A.H., Fairlamb A.H., Fairlamb A.H., Fernández M.L., Ferreira R.C., Filardi L.S., Fonseca-Berzal C., Garavaglia P.A., Goijman S.G., Gupta S., Gurumurthy M., Hall B.S., Hall B.S., Hayashi M., Henderson G.B., Henderson G.B., Henriques C., Ivens A.C., Jacobs R.T., Janssens P.G., Jeganathan S., Jennings F.W., Kaiser M., Kubata B.K., Lewis M.D., Lewis M.D., Lewis M.D., Likeufack A.C.L., Maina N., Makarov V., Marin-Neto J.A., Marin-Neto J.A., Matsumoto M., Maya J.D., Mejia A.M., Mejía-Jaramillo A.M., Mesu V.K.B.K., Miura K., Moens F., Molina I., Moreno M., Moreno S.N.J., Morillo C.A., Morillo C.A., Mortelmans K., Mukherjee T., Mukkavilli R., Murta S.M., Murta S.M.F., Murta S.M.F., Neal R.A., Nesslany F., Nogoceke E., Nogueira F.B., Nogueira F.B., Olmo F., Panicucci R., Papadopoulou M.V., Papadopoulou M.V., Papadopoulou M.V., Patterson S., Patterson S., Patterson S., Portal P., Priotto G., Priotto G., Pépin J., Pépin J., Raether W., Repetto Y., Rodriques Coura J., Romero A.H., Ryan N.J., Sasahara K., Shimokawa Y., Singh R., Smith D.A., Sokolova A.Y., Stephen Patterson, Stover C.K., Stuart K., Tarleton R.L., Tarral A., Temperton N.J., Thompson A.M., Thompson A.M., Thompson A.M., Thompson A.M., Thompson A.M., Torreele E., Trochine A., Trochine A., Trunz B.B., Tweats D., Urbina J.A., Viodé C., Walsh J.S., Wilkinson S.R., Winkelmann E., Wyllie S., Wyllie S., Wyllie S., Wyllie S., Zhou L.   +141 more
core   +2 more sources

Human African trypanosomiasis : current status and eradication efforts [PDF]

, 2020
Epidemics of human African trypanosomiasis (HAT) in the 20th century led to millions of deaths. However, since the start of the twenty-first century, there is been a continued decline in the number of reported cases, due to increased investment and ...
Davis, Christopher, Keeling, Matthew James, Rock, Kat S.   +2 more
core   +1 more source

Nifurtimox Is Ineffective against Drug-Resistant Mycobacteria [PDF]

Antimicrobial Agents and Chemotherapy, 2017
Contains fulltext : 177442.pdf (Publisher’s version ) (Open Access)
Mike Marvin Ruth, Jasper Jan Nicolaas Sangen, Heiman Frank Louis Wertheim, Jakko van Ingen   +3 more
openaire   +4 more sources

Contribution of microscopy for understanding the mechanism of action against trypanosomatids [PDF]

, 2018
Transmission electron microscopy (TEM) has proved to be a useful tool to study the ultrastructural alterations and the target organelles of new antitrypanosomatid drugs.
A Martinez-Palomo, A Montalvetti, A Rassi, AB Penissi, AE Eakin, AH Kolien, AJ Solari, AM Sánchez, Ana Yecê das Neves Pinto, C Brack, CF Silva Da, D Gonzalez-Pacanowska, DA Campbell, DA Johnston, DJ Hammond, DV Andrade, E Bontempi, E Lozano, E Lozano, E Lozano, EO Ogbadoiyi, ES Garcia, ES Lozano, F Dos Reis, FR Opperdoes, FR Opperdoes, FR Opperdoes, FS Laranja, H Meyer, H Meyer, J Aldunate, J Lukes, J McKerrow, J Mottram, JA Urbina, JA Urbina, JA Urbina, JA Urbina, JC Engel, JC Linder, JCP Dias, JCP Dias, JD Bergstrom, JD Maya, JF Turrens, JJ Marr, JL Avila, JL Avila, Juliano de Toledo, K Lazardi, K Miranda, K Miranda, KH Lee, L Simpson, LV Muschietti, M Meirelles, M Nieto, MC Elias, MCQB Elias, MR Ariyanayagam, MR Ariyanayagam, NM Sayed El, O Campetella, OS Giordano, OS Giordano, P Barrera, P Webster, PF Pimenta, R Docampo, S Sepúlveda-Boza, SD Brengio, SR Wilkinson, T Souto-Padron, T Souto-Padron, T Souto-Padron, T Souto-Padron, TA Shapiro, TS Tiuman, V Jimenez-Ortiz, V Sülsen, VP Sülsen, VP Sülsen, VV Costantino, W Souza De, W Souza De, W Souza De, W Souza De, W Souza De, W Souza De, Wanderley de Souza, WE Gutteridge   +90 more
core   +1 more source

Tratamento da forma indeterminada da doença de Chagas com nifurtimox e benzonidazol

Revista da Sociedade Brasileira de Medicina Tropical, 1990
Cem portadores da forma indeterminada da doença de Chagas, com xenodiagnóstico e sorologia positivos, foram tratados no período de 1965 a 1985. Destes, metade, com nifurtimox (Bayer) e os outros cinqüenta, com benzonidazol(Roche).
Humberto de Oliveira Ferreira
doaj   +3 more sources

Congenital Chagas Disease in the United States: Cost Savings Through Maternal Screening [PDF]

, 2018
Chagas disease, caused by Trypanosoma cruzi, is transmitted by insect vectors through transfusions, transplants, insect feces in food, and from mother to child during gestation.
Bialek, Stephanie R., Montgomery, Susan P., Perez-Zetune, Victoria, Stillwaggon, Eileen   +3 more
core   +2 more sources